

Special Issue

Antigens in Cancer

Message from the Guest Editor

In this special issue, we are particularly interested in papers that report on the identification and/or characterization of novel antigens in cancer and different agents that target these novel antigens. Moreover, papers leading to the development of specific methodologies aiming at the better screening/identification/quantification of cancer antigens would be of great interest. Reviews that summarize current knowledge gained from the preclinical and clinical studies of TCR- and CAR-T cells against cancer would be particularly useful. Potential topics include, but are not limited to:

- Identification or prioritization of novel cancer antigens
- Methodologies for the detection of cancer antigens
- Next-generation or fine-tuning of TCR or CAR constructs to overcome immune suppression or avoid toxicity
- Novel cancer-antigen-specific small molecules or peptides as carriers of cytotoxic drugs or radioisotopes
- Novel antibody designs and formats for improved pharmacokinetics or conjugation with cytotoxic drugs or radioisotopes.

Guest Editor

Prof. Dr. Moonsoo Jin

Department of Surgery, Weill Cornell Medicine, New York, NY 10065, USA

Deadline for manuscript submissions

closed (20 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/116091

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)